Sparks - Elicera Therapeutics

Elicera Therapeutics has announced that its Phase I/IIa CARMA trial, investigating its CAR-T therapy ELC-301 for B-cell lymphoma, is progressing to patient dosing in cohort 2 following clearance from the Data Safety and Monitoring Board (DSMB). The DSMB completed its first assessment of the trial following a review of cohort 1. The company had reported a complete response in the first treated patient at the initial one-month follow-up, with no serious adverse events, and two further patients were treated at the lowest dose with no safety concerns. The DSMB recommended that the CARMA study goes ahead as planned, testing patients at the next dose level in cohort 2. Management plans to announce preliminary results as each dosing cohort is completed, with preliminary efficacy data from cohort 1 due to be presented at the 7th Swedish Cancer Research Meeting in Malmö on 22 May 2025.

ELC-301 is a fourth-generation CAR-T therapy targeting the CD20 antigen, armed with the company’s proprietary immunotherapies Activated with NAP for efficient Killing (iTANK) platform, intended to activate broader and more comprehensive immune responses against cancer.